Recombinant Technologies
Private Company
Funding information not available
Overview
Recombinant Technologies is an emerging biotech firm developing the AmyTrap platform, a proprietary approach to sequester and remove toxic beta-amyloid as a treatment for Alzheimer's disease and related beta-amyloidopathies. The company's lead asset, AmyTrap-3, is a small molecule queued for IND-enabling studies, supported by proof-of-concept data and multiple NIH SBIR grants. RTL is privately funded, pre-revenue, and operates out of New Haven, Connecticut, with a vision to expand its technology to other neurodegenerative indications.
Technology Platform
AmyTrap platform: Proprietary small molecules and a plasma-filtration device (AmyTrapper) designed to capture and remove beta-amyloid peptides from the bloodstream, creating a peripheral sink to draw amyloid out of the brain.
Opportunities
Risk Factors
Competitive Landscape
RTL competes in the crowded Alzheimer's disease space dominated by large pharma and biotech firms, including those with approved anti-amyloid antibodies (Eisai/Biogen's Leqembi). Its differentiation lies in its peripheral small molecule/device approach, which aims for a better safety profile, but it trails far behind clinical-stage competitors.